CALGB 140503 trial: what clinicians have said so far
Comparison of Different Types of Surgery in Treating Patients With Stage IA Non-Small Cell Lung Cancer
- NCT00499330 ↗
- Active, not recruiting
- Alliance for Clinical Trials in Oncology
- Deep size, estimated: 301+ verified statements once built
We haven't built an HCP commentary report on CALGB 140503 (stage IA non-small cell lung cancer; tests a strategy, not a drug) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Some of the questions raised in the 40 most recent indexed sources
Automated from the 40 newest of 81 indexed sources (Feb 2023 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether wedge resection and segmentectomy perform alike within the sublobar arm, and which segments were resected
- Whether a fuller lymph node dissection is needed after negative intraoperative frozen-section nodal sampling
- Whether tumors upstaged for visceral pleural invasion call for adjuvant systemic therapy trials rather than a larger resection
- How second primary lung cancers after lobar versus sublobar resection should weigh on preserving lung tissue
Indexed commentary on CALGB 140503 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 79 posts on X, typically up to 348 once built | |
| 2 YouTube videos, typically up to 9 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase III Randomized Trial of Lobectomy Versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
- Phase
- Phase not given
- Status
- Active, not recruiting
- Conditions
- Lung Cancer
- Interventions
- lobectomy; segmentectomy or wedge resection
- Arms
- Arm A · Other
- Arm B · Experimental
- Enrollment
- Not given
- Primary outcomes
- disease-free survival
- Sponsor
- Alliance for Clinical Trials in Oncology with National Cancer Institute (NCI)
- Start
- Oct 12, 2007
- Primary completion
- Apr 4, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT00499330 · updated Jul 16, 2026
Publications
linked from the registry- Ganti AK, Damman B, Wang X, Stinchcombe TE, Altorki N. Outcomes Based on Age in CALGB 140503 (Alliance): Lobar Versus Sublobar Resection for Peripheral Stage IA Non-small Cell Lung Cancer. Clin Lung Cancer. 2026 Jul 2;27(7):42-49. doi: 10.1016/j.cllc.2026.06.009. Online ahead of print. PubMed 42501610
- Altorki N, Damman B, Wang X, Liberman M, Wigle D, Ashrafi A, Conti M, Yasufuku K, Schuchert MJ, Stinchcombe TE. The extent of lymph node dissection is not associated with disease-free survival following lobar or sublobar resection: Results from Cancer and Leukemia Group B 140503 (Alliance). J Thorac Cardiovasc Surg. 2025 Oct;170(4):933-942.e2. doi: 10.1016/j.jtcvs.2025.06.007. Epub 2025 Jun 16. PubMed 40532782
- Stinchcombe TE, Wang X, Damman B, Mentlick J, Landreneau R, Wigle D, Jones DR, Conti M, Ashrafi AS, Liberman M, de Perrot M, Mitchell JD, Keenan R, Bauer T, Miller D, Altorki N. Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non-Small-Cell Lung Cancer. J Clin Oncol. 2024 Apr 1;42(10):1110-1113. doi: 10.1200/JCO.23.01306. Epub 2024 Jan 12. PubMed 38215351
- Altorki N, Wang X, Kozono D, Watt C, Landrenau R, Wigle D, Port J, Jones DR, Conti M, Ashrafi AS, Liberman M, Yasufuku K, Yang S, Mitchell JD, Pass H, Keenan R, Bauer T, Miller D, Kohman LJ, Stinchcombe TE, Vokes E. Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer. N Engl J Med. 2023 Feb 9;388(6):489-498. doi: 10.1056/NEJMoa2212083. PubMed 36780674
- Altorki NK, Wang X, Wigle D, Gu L, Darling G, Ashrafi AS, Landrenau R, Miller D, Liberman M, Jones DR, Keenan R, Conti M, Wright G, Veit LJ, Ramalingam SS, Kamel M, Pass HI, Mitchell JD, Stinchcombe T, Vokes E, Kohman LJ. Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). Lancet Respir Med. 2018 Dec;6(12):915-924. doi: 10.1016/S2213-2600(18)30411-9. Epub 2018 Nov 12. PubMed 30442588